Value through Innovation28 November 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases

- For media outside of the US, the UK & Canada only

Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial, and their respiratory pipeline products in COPD, asthma, IPF and lung cancer at ERS 2013

- For media outside the UK, US and Canada

New treatment for cats with chronic kidney disease: Boehringer Ingelheim launches Semintra®


ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations

- For media outside of the US, the UK & Canada only

Boehringer Ingelheim takes a further step to establish Animal Health business in Asia


Boehringer Ingelheim announces full patient enrolment for two of its pivotal Phase III interferon-free hepatitis C clinical trials

- For media outside USA, UK and Canada only

Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet

- For Non-US and Non-UK Media

First half year 2013: Boehringer Ingelheim remains on growth path


Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints

- For non U.S. Media Only

First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes

- For Non-US and Non-UK Media

Afatinib receives positive CHMP opinion for patients with EGFR mutation positive lung cancer in European Union

- For non U.S. Media Only

Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding


Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure

- For media outside of the US, the UK & Canada only

Healthrageous, United BioSource and Boehringer Ingelheim launch SMART digital diabetes Study


U.S. FDA approves Gilotrif™ (afatinib)* as first-line treatment for lung cancer patients with EGFR mutations

- For non U.S. Media Only

Boehringer Ingelheim and Ashoka Changemakers Announce Winners of Transforming Health Systems Competition


Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product


Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA

- For Non-U.S. and Non-UK media